BioMedomics Inc (USA) has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. This test detects both IgM/IgG antibodies in human finger-prick or venous blood samples. It can also be used to test human serum or plasma samples.

This CE marked test can be used as a point of care test for rapid screening to identify individuals who have been previously exposed to the virus. Studies suggest that a significant percentage of patients show no clinical symptoms of the virus, thus screening patients is vitally important in the fight against this global threat.

This kit is registered with the MHRA and sold in the UK

For Professional Use only.

• Detection of IgM and IgG antibodies to COVID-19 in a single test
• Suitable for whole blood, serum and plasma samples
• Results in 10 minutes
• Validated using PCR
• Visual interpretation
• No special facilities or equipment necessary
• No specialised training required
• Room temperature storage
• CE Marked